Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV)
Authors:
- 18 April 2011
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 108 (17) , 6739-6744
Abstract
The search for novel therapeutic interventions for viral disease is a challenging pursuit, hallmarked by the paucity of antiviral agents currently prescribed. Targeting of viral proteins has the inextricable challenge of rise of resistance. Safe and effective vaccines are not possible for many viral pathogens. New approaches are required to address the unmet medical need in this area. We undertook a cell-based high-throughput screen to identify leads for development of drugs to treat respiratory syncytial virus (RSV), a serious pediatric pathogen. We identified compounds that are potent (nanomolar) inhibitors of RSV in vitro in HEp-2 cells and in primary human bronchial epithelial cells and were shown to act postentry. Interestingly, two scaffolds exhibited broad-spectrum activity among multiple RNA viruses. Using the chemical matter as a probe, we identified the targets and identified a common cellular pathway: the de novo pyrimidine biosynthesis pathway. Both targets were validated in vitro and showed no significant cell cytotoxicity except for activity against proliferative B- and T-type lymphoid cells. Corollary to this finding was to understand the consequences of inhibition of the target to the host. An in vivo assessment for antiviral efficacy failed to demonstrate reduced viral load, but revealed microscopic changes and a trend toward reduced pyrimidine pools and findings in histopathology. We present here a discovery program that includes screen, target identification, validation, and druggability that can be broadly applied to identify and interrogate other host factors for antiviral effect starting from chemical matter of unknown target/mechanism of action.Keywords
This publication has 53 references indexed in Scilit:
- Diversity-oriented synthesis as a tool for the discovery of novel biologically active small moleculesNature Communications, 2010
- Robust and Sensitive iTRAQ Quantification on an LTQ Orbitrap Mass SpectrometerMolecular & Cellular Proteomics, 2008
- Post-Infection A77-1726 Blocks Pathophysiologic Sequelae of Respiratory Syncytial Virus InfectionAmerican Journal of Respiratory Cell and Molecular Biology, 2007
- Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitorsNature Biotechnology, 2007
- Determining druggabilityNature Reviews Drug Discovery, 2007
- Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantationTransplant Infectious Disease, 2007
- Respiratory Syncytial Virus Infection in Elderly and High-Risk AdultsNew England Journal of Medicine, 2005
- Nucleotide-mediated inhibition of alveolar fluid clearance in BALB/c mice after respiratory syncytial virus infectionAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2004
- Respiratory syncytial virus epidemics: the ups and downs of a seasonal virusThe Pediatric Infectious Disease Journal, 2003
- A mutation that uncouples allosteric regulation of carbamyl phosphate synthetase in DrosophilaJournal of Molecular Biology, 1999